Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:33 AM
Ignite Modification Date:
2025-12-25 @ 12:33 AM
NCT ID:
NCT00104767
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed non-small cell lung cancer
* Stage IIIB or IV disease
* Radiographically measurable disease
* 18 and over
* Performance status: ECOG 0-2
* Renal: Creatinine ≤ 2 mg/dL
* Negative pregnancy test
* Fertile patients must use effective contraception
* More than 4 weeks since prior chemotherapy
* Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids
* Radiotherapy: More than 4 weeks since prior radiotherapy
* More than 4 weeks since other prior anticancer therapy
* More than 4 weeks since prior non-cytotoxic investigational agents
* At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs)
Exclusion Criteria:
* pregnant or nursing
* comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements
* hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent
* history of gastrointestinal ulceration, bleeding, or perforation
* other concurrent cyclooxygenase-2 or -3 inhibitors
* other concurrent NSAIDs
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00104767
Study Brief:
Protocol Section:
NCT00104767